ASO-LINC02568

ASO-LINC02568 is an experimental **antisense oligonucleotide** designed to silence the long non-coding RNA **LINC02568** in estrogen receptor-positive breast cancer. Based on the published preclinical study, LINC02568 is an estrogen-induced oncogenic lncRNA that promotes tumor growth and endocrine therapy resistance through dual biology: it supports **ESR1** signaling in trans by stabilizing ESR1 mRNA via a miR-1233-5p-related mechanism, and it supports tumor pH homeostasis in cis through regulation of **CA12**. In vitro and in vivo, antisense targeting of LINC02568 inhibited ER-positive breast cancer growth, and combination treatment showed synergistic effects with endocrine therapy agents and with the CA12 inhibitor U-104. No evidence from the provided source identifies a formal commercial developer, brand name, or clinical-stage program for this specific ASO.

Other names

LINC02568 antisense oligonucleotideLINC-02568 antisense oligonucleotideLINC 02568 antisense oligonucleotideantisense oligonucleotide targeting LINC02568